^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.3.1.8
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
TEAEs of Sp
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Safety Analy

                       JM_AVAL_      JM_AVAL_      JM_AVAL_
 JM_TYPE               LABEL         COUNTC        NAMEC
             JM_BIGN_                     JM_AVAL_  JM_AVAL_
 JM_BLOCK    WHERE         trtVAR            COUNT      BIGN
             JM_AVAL_  JM_SECONDARY_
 JM_TRTVARN     NAMEN  WHERE
 ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 COUNT                 Number of     2 (20.0)         Y        
                       participants                            
                       with at                                 
                       least one                               
                       TEAE                                    
 101         saffl='Y'     JZP150 0.3 mg         2        10
          1         1               

 COUNT                 Number of     2 (7.1)          Y        
                       participants                            
                       with at                                 
                       least one                               
                       TEAE                                    
 101         saffl='Y'     JZP150 Total          2        28
         99         2               
 
 
^S={}AE: Adverse Event; TEAE: Treatment-Emergent Adverse Event.
^S={}Note: The Safety Analysis Set includes all participants who
^S={}Note: A TEAE is generally defined as any event with onset d
^S={}Note: TEAEs have been coded using the MedDRA dictionary, ve
^S={}Note: Participants reporting an AE more than once within a 
^S={}Note: Percentages are based on the total number reported in
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.3.1.8
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
TEAEs of Sp
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Safety Analy

                       JM_AVAL_      JM_AVAL_      JM_AVAL_
 JM_TYPE               LABEL         COUNTC        NAMEC
             JM_BIGN_                     JM_AVAL_  JM_AVAL_
 JM_BLOCK    WHERE         trtVAR            COUNT      BIGN
             JM_AVAL_  JM_SECONDARY_
 JM_TRTVARN     NAMEN  WHERE
 ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 COUNT                 Number of     3 (15.0)         Y        
                       participants                            
                       with at                                 
                       least one                               
                       TEAE                                    
 101         saffl='Y'     Placebo               3        20
          3         3               
 
 
 
 
 
 
 
 
 
 
^S={}AE: Adverse Event; TEAE: Treatment-Emergent Adverse Event.
^S={}Note: The Safety Analysis Set includes all participants who
^S={}Note: A TEAE is generally defined as any event with onset d
^S={}Note: TEAEs have been coded using the MedDRA dictionary, ve
^S={}Note: Participants reporting an AE more than once within a 
^S={}Note: Percentages are based on the total number reported in
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
